Page 33 - วารสารการแพทย์แผนไทย ปีที่ 20 ฉบับที่ 2 พฤษภาคม-สิงหาคม 2565
P. 33

J Thai Trad Alt Med                                   Vol. 20  No. 2  May-Aug  2022  231




            good, and 21.28% vs. 17.39% as fair. The global   statistically significantly different (p = 0.875).
            assessment results of both groups were not   Similarly, the amount of paracetamol taken by



            Table 2  VAS pain scores (Mean ± S.D.) at baseline and days after intervention with diclofenac and Justicia gendarussa
                   Burm.f. medicated sprays.
                                           VAS pain scores (Mean ± S.D.)
                                    Baseline  Day 1   Day 2   Day 3   Day 4   Day 5   Day 6   Day 7

            Diclofenac spray        5.68 ±   5.33 ±  4.54 ±  3.93 ±  3.30 ±  2.78 ±  2.04 ±  2.21 ±
                                     1.63    1.61   1.31    1.50   1.49    1.47    1.55   1.50

            Justicia gendarussa spray   5.94 ±  5.17 ±   4.83 ±  4.23 ±  3.79 ±  3.02 ±   2.70 ±  2.34 ±
                                     1.67    1.81   1.80    1.90   1.88    2.01    2.18   1.82
            * p-value               0.450   0.867  0.395  0.379  0.843    0.459   0.088  0.680
                   †
            * Mixed-effects linear regression model
            † Adjusted for gender


            Table 3  Percentages and numbers of patients who had swelling of the affected areas and the risk ratio of swelling at a
                   baseline and at post-treatment in the diclofenac spray and Justicia gendarussa Burm.f. medicated spray groups.

                                     Diclofenac spray   Justicia gendarussa   p-value    Risk ratio (95%CI) †
                                     (n = 46)      spray (n = 45)
            Swelling at baseline     100.00% (47)   97.87% (46)
            Swelling after treatment   54.35% (25)   53.33% (24)    0.951    0.988 (0.660 to 1.478)
            p-value                  < 0.001       < 0.001

            Values were shown as Percentage (Number)
            † Adjusted for gender



            groups (p = 0.951). While, the JGS group could   in each day. Meanwhile, as shown in Table 4,

            reduce swelling at the risk ratio of 0.988 (95%   the assessment result was not statistically
            confidence interval, 0.66-1.478) at Day 7 when   different (p = 0.447).
            compared to the DFS group.                       The global assessment results in each

                 Three days after using DFS in comparison   group evaluated the efficacy of the medication
            with JGS to treat the patients for soft tissue   they received on a scale of 1 to 3 (1 = fair, 2 =

            injury, the clinical improvement of JGS group   good, and 3 = very good). The results for DFS
            according to the hazard ratio was improved   versus JGS, as shown in Figure 2, were 19.5%
            faster than that of the DFS group by 1.18 time   vs. 17.39% as very good, 59.57% vs. 65.22% as
   28   29   30   31   32   33   34   35   36   37   38